Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects

@article{SargentiniMaier2008PharmacokineticsAM,
  title={Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects},
  author={Maria Laura Sargentini-Maier and Pascal Espi{\'e} and Alain Coquette and Armel Stockis},
  journal={Drug Metabolism and Disposition},
  year={2008},
  volume={36},
  pages={36 - 45}
}
This study was designed to investigate the human absorption, disposition, and mass balance of 14C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of 14C-brivaracetam (150 mg, 82 μCi, or 3.03 MBq). Serial blood and complete urine and feces were collected until 144 h postdose. Expired air samples were obtained until 24 h. Brivaracetam was rapidly absorbed, with Cmax of 4 μg/ml occurring within 1.5 h of… 

Figures and Tables from this paper

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
TLDR
Brivaracetam had a favourable pharmacokinetic profile in this population, characterized by rapid absorption, volume of distribution limited to total body water, apparent single-compartment elimination and dose proportionality.
Brivaracetam Disposition in Renal Impairment
TLDR
It is suggested that dose adjustment of brivaracetam should not be required at any stage of renal dysfunction, and the absence of safety issues related to the increased levels of metabolites is concluded.
Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis
TLDR
In vitro data indicated that the enzyme was not significantly inhibited nor induced by rifampin, and pharmacokinetic modeling confirmed that all of the observed changes in vivo were secondary to the induction of the CYP2C19-mediated hydroxylation of BRV to BRV-OH.
Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50‐mg Film‐Coated Tablet
TLDR
An oral solution formulation of brivaracetam has been developed to provide an additional treatment option for patients who have difficulty in swallowing tablets to assess the relative bioavailability and bioequivalence of bri varacetam oral solution and 50-mg tablet after single administration in healthy participants.
Effect of brivaracetam on CYP3A activity, measured by oral midazolam
TLDR
Brivaracetam up to 150 mg/day has no significant inducing or inhibiting effect on CYP3A activity, and the areas under the plasma concentration‐time curves from 0 to infinity (AUCinf) for midazolam and 1′‐hydroxymidazol am were similar on Days 13 and 20 compared with Day 1.
Effect of Gemfibrozil on the Metabolism of Brivaracetam In Vitro and in Human Subjects
TLDR
Investigation of the effect of gemfibrozil and its 1-O-β-glucuronide on BRV disposition both in vivo (healthy participants) and in vitro (human liver microsomes and hepatocytes) suggests that CYP2C8 and CYP3C9 are not involved in BRV hydroxylation, whereas hydroxYLation of BRV-AC toBRV-OHAC is likely to be mediated by CYP9.
Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.
TLDR
Results suggest that brivaracetam is hydroxylated by CYP2C19, but this pathway is minor compared with hydrolysis to the acid metabolite.
Brivaracetam Disposition in Mild to Severe Hepatic Impairment
TLDR
Exposure to brivaracetam increased by 50–60% in patients with hepatic impairment, irrespective of severity and the relative importance of biotransformation pathways was altered; cytochrome P450‐dependent hydroxylation decreased; CYP‐independent acid metabolite formation increased concomitantly.
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
TLDR
Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose and was found to have desirable pharmacokinetic properties.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers
TLDR
The absorption, disposition and metabolism of levetiracetam, a new antiepileptic drug, have been investigated after a single oral dose of the 14C-labelled molecule administered to male healthy volunteers and there was no evidence of chiral inversion.
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
TLDR
Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose and was found to have desirable pharmacokinetic properties.
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
TLDR
The findings show that brivaracetam clearly suppresses generalized photoparoxysmal EEG response, and investigations of the antiepileptic properties and tolerability of bri varacetam are warranted in further clinical studies of patients with epilepsy.
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
TLDR
The pharmacological studies from this group led to the selection of (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide 83alpha (ucb 34714) as the most interesting candidate, approximately 10 times more potent than 2 as an antiseizure agent in audiogenic seizure-prone mice.
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
  • B. Lynch, N. Lambeng, B. Fuks
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2004
TLDR
The experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2 a, supporting previous indications that LEv possesses a mechanism of action distinct from that of other antiepileptic drugs.
Increased Numbers of Coassembled PSD‐95 to NMDA‐receptor Subunits NR2B and NR1 in Human Epileptic Cortical Dysplasia
TLDR
This study quantitatively investigated the coassembly of PSD‐95 to NR2B and NR1 in human epileptogenic cortex as compared with nonepileptic cortex.
[RECOMMENDATIONS of the International Commission on Radiological Protection].
  • R. Sievert, G. Failla
  • Physics
    Journal de radiologie, d'electrologie & archives d'electricite medicale
  • 1955
TLDR
Recommendations are presented which represent concepts and practices evolved from recent discussions at formal and informal meetings of the Commission and its Committees.
UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo
  • Epilepsia
  • 2003
UCB 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo
  • Epilepsia
  • 2003
Brivaracetam safety, tolerability, pharmacokinetics and CNS pharmacodynamic effects after 10 to 1400 mg single rising oral doses in healthy males
  • Br J Clin Pharmacol
  • 2007
...
1
2
...